How to Use Statins in Secondary Prevention of Atherosclerotic Diseases: from the Beneficial Early Initiation to the Potentially Unfavorable Discontinuation.

Published on Aug 4, 2021in Cardiovascular Drugs and Therapy4.069
· DOI :10.1007/S10557-021-07233-8
Nikolaos P.E. Kadoglou (UCY: University of Cyprus), Marianna Stasinopoulou4
Estimated H-index: 4
(Academy of Athens)
Source
Abstract
Statins, a class of lipid-lowering drugs, reduce morbidity and mortality in patients with established atherosclerosis-related cardiovascular disease. Early initiation of statin therapy after admission for acute coronary syndromes (ACS), stroke, or transient ischemic attack (TIA) is associated with improved cardiovascular outcomes. Moreover, high-dose statin treatment prior to coronary or carotid revascularization has been shown to reduce cardiovascular events in these patients. However, many patients may be undertreated, and a residual cardiovascular risk remains in current clinical practice. Despite the beneficial role of statins, their discontinuation rate among patients is still elevated leading to severe adverse cardiovascular events due to atherosclerotic plaque destabilization. In this review, we summarized the impact of statin treatment among patients, focusing on the initiation time-points as well as the potential harm derived by their discontinuation.
📖 Papers frequently viewed together
7 Citations
10 Citations
1 Citations
References73
Newest
AIMS Clinical management of patients more than 1 year after acute myocardial infarction (MI) is challenging. Patient risk stratification may help to establish therapeutic priorities. We aimed to describe the comprehensive risk profile and management of patients with prior MI. METHODS We analyzed data from the EYESHOT Post-MI study, which evaluated the management of patients 1-3 years after MI. The risk profile of participants was defined according to the qualifying high-risk features of the PEGA...
1 CitationsSource
#1Emily Herrett (Lond: University of London)H-Index: 17
#2Elizabeth A. Williamson (Lond: University of London)H-Index: 73
Last. Liam Smeeth (Lond: University of London)H-Index: 115
view all 20 authors...
Abstract Objective To establish the effect of statins on muscle symptoms in people who had previously reported muscle symptoms when taking statins. Design Series of randomised, placebo controlled n-of-1 trials. Setting Primary care across 50 sites in the United Kingdom, December 2016 to April 2018. Participants 200 participants who had recently stopped or were considering stopping treatment with statins because of muscle symptoms. Interventions Participants were randomised to a sequence of six d...
17 CitationsSource
#1Ulf Landmesser (Charité)H-Index: 104
#2Angela PirilloH-Index: 31
Last. Alberico L. Catapano (University of Milan)H-Index: 96
view all 14 authors...
Abstract Background and aims Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. Aim of this survey was to evaluate the compliance to ESC/EAS guidelines during the management of ACS patients and the effectiveness of secondary prevention in seven European countries. Methods By means of an online questionnaire, data on 2775 ACS patients (either acute case or follow-up patients) were ...
3 CitationsSource
#1Baris Gencer (Harvard University)H-Index: 25
#2Nicholas A Marston (Harvard University)H-Index: 1
Last. Marc S. Sabatine (Harvard University)H-Index: 119
view all 9 authors...
Summary Background The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients. Methods In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles published between March 1, 2015, and Aug 14, 2020, without any language restrictions. We included randomised controlled trials of cardiovascular outcomes of an LDL cholesterol-lowering drug recommen...
26 CitationsSource
#1Helen J Curtis (University of Oxford)H-Index: 17
#2Alex J Walker (University of Oxford)H-Index: 20
Last. Ben Goldacre (University of Oxford)H-Index: 37
view all 5 authors...
BACKGROUND Since 2014 English national guidance recommends 'high-intensity' statins, reducing low-density lipoprotein (LDL) cholesterol by ≥40%. AIM To describe trends and variation in low-/medium-intensity statin prescribing and assess the feasibility of rapid prescribing behaviour change. DESIGN AND SETTING A retrospective cohort study using OpenPrescribing data from all 8142 standard NHS general practices in England from August 2010 to March 2019. METHOD Statins were categorised as high- or l...
3 CitationsSource
#1Marianne Vie Ingersgaard (Steno Diabetes Center)H-Index: 2
#2Tue Helms Andersen (Steno Diabetes Center)H-Index: 5
Last. Kasper Olesen (Steno Diabetes Center)H-Index: 6
view all 5 authors...
Purpose: Lipid-lowering medications are often prescribed to decrease the risk of micro- and macro-cardiovascular complications related to dyslipidaemia. Despite widespread prescription of lipid-lowering drugs, including statins, adherence to therapy is a challenge worldwide. This systematic review of reviews aimed to conduct a critical appraisal and synthesis of review findings and to provide an overview of the factors that were found to affect adherence to lipid-lowering drugs, focusing on stat...
8 CitationsSource
#1François MachH-Index: 79
#2Colin BaigentH-Index: 81
Last. Brian A. FerenceH-Index: 26
view all 121 authors...
1,610 CitationsSource
#1Scott M. GrundyH-Index: 212
#2Neil J. StoneH-Index: 56
Last. Joseph YeboahH-Index: 29
view all 24 authors...
Glenn N. Levine, MD, FACC, FAHA, Chair Patrick T. O’Gara, MD, MACC, FAHA, Chair-Elect Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair [‡‡‡][1] Sana M. Al-Khatib, MD, MHS, FACC, FAHA Joshua A. Beckman, MD, MS, FAHA Kim K. Birtcher, PharmD, MS, AACC Biykem Bozkurt, MD, PhD,
1,903 CitationsSource
#1Marianna Stasinopoulou (Academy of Athens)H-Index: 4
#2Nikolaos P.E. Kadoglou (University of Oxford)H-Index: 9
Last. John D. Kakisis (UoA: National and Kapodistrian University of Athens)H-Index: 31
view all 8 authors...
BACKGROUND: To evaluate the impact of atorvastatin discontinuation on the progression and stability of atherosclerotic plaques in a valid animal model of atherosclerosis. METHODS: Seventy ApoE-/- male mice fed with high-fat diet were randomly assigned into: (1) long-term intervention groups: (i) ATL, received atorvastatin for 12 weeks, (ii) CO-12W, control received vehicle for 12 weeks, (iii) ATW-6W, received atorvastatin for 6 weeks which was withdrawn for another 6 weeks. (2) Short-term interv...
4 CitationsSource
#1Mohamad Soud (MedStar Washington Hospital Center)H-Index: 6
#2Gavin Ho (MedStar Washington Hospital Center)H-Index: 3
Last. Hector M. Garcia-Garcia (MedStar Washington Hospital Center)H-Index: 29
view all 6 authors...
Summary It has been shown that statins preloading, before percutaneous coronary intervention (PCI), may reduce the risk of cardiovascular outcomes for acute coronary syndrome patients. Nevertheless, the effect of such pretreatment among patients with stable angina pectoris (SAP) is still debatable. We performed a systematic review and updated meta-analysis of the literature to evaluate the efficacy of short-term statins preloading on periprocedural myocardial infarction (PMI) incidence and morta...
4 CitationsSource
Cited By0
Newest